Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease

We read with interest the article “Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease” by Ollech et al.1 They describe ustekinumab dose interval shortening from 90 mg every 8 weeks to every 4 weeks in 110 patients with Crohn’s disease. Clinical remission (HBI, ≤4) was achieved in 50.9% at the last follow-up evaluation, with no serious adverse events reported. This is an important study that adds to the limited data to date supporting dose optimization at greater than 90 mg every 8 weeks.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research